News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,490 Results
Type
Article (8051)
Company Profile (140)
Press Release (476298)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166753)
Career Advice (304)
Deals (25738)
Drug Delivery (7)
Drug Development (52911)
Employer Resources (14)
FDA (9764)
Job Trends (8583)
News (238221)
Policy (17904)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33154)
ALS (104)
Alzheimer's disease (976)
Antibody-drug conjugate (ADC) (262)
Approvals (10372)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6968)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (507)
Cancer (3628)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47872)
Collaboration (1239)
Commercialization (3)
Compensation (1449)
Complete response letters (34)
COVID-19 (761)
CRISPR (63)
C-suite (738)
Cystic fibrosis (85)
Data (5627)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4180)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73678)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87585)
Executive appointments (698)
FDA (12371)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (911)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (292)
Government (943)
Grass and pollen (2)
Guidances (281)
Healthcare (9315)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (156)
Infectious disease (949)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1969)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (60)
Legal (5196)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (505)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (529)
Marketing (8)
MASH (119)
Medical device (8650)
Medtech (8790)
Mergers & acquisitions (14378)
Metabolic disorders (705)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1820)
NextGen: Class of 2026 (3157)
Non-profit (842)
Obesity (223)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (502)
Peanut (31)
People (41216)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15477)
Phase 2 (21391)
Phase 3 (14414)
Pipeline (7238)
Policy (18)
Postmarket research (1570)
Preclinical (6537)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3019)
Recruiting (6)
Regulatory (14796)
Reports (20)
Research institute (582)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Supply chain (50)
Vaccines (318)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Last 7 days (457)
Last 30 days (1591)
Last 365 days (19030)
2026 (12079)
2025 (19255)
2024 (22986)
2023 (26541)
2022 (34599)
2021 (37177)
2020 (33488)
2019 (23262)
2018 (17497)
2017 (18767)
2016 (17918)
2015 (24263)
2014 (21681)
2013 (18135)
2012 (20222)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17890)
Australia (2097)
California (11905)
Canada (3127)
China (517)
Colorado (481)
Connecticut (407)
Delaware (207)
Europe (24632)
Florida (1780)
Georgia (375)
Hawaii (3)
Idaho (46)
Illinois (695)
India (48)
Indiana (314)
Iowa (14)
Japan (398)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1193)
Massachusetts (7825)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2612)
New Mexico (12)
New York (2811)
North Carolina (1267)
North Dakota (4)
Northern California (5961)
Ohio (276)
Oklahoma (14)
Oregon (16)
Pennsylvania (2244)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4942)
Tennessee (119)
Texas (1925)
United States (38675)
Utah (358)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (921)
West Virginia (1)
Wisconsin (73)
484,490 Results for "scynexis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
·
10 min read
Press Releases
SCYNEXIS Announces One-for-Eight Reverse Stock Split - May 22, 2026
May 25, 2026
·
5 min read
Press Releases
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 11, 2026
·
10 min read
Press Releases
SCYNEXIS Announces $40.0 Million Private Placement
March 31, 2026
·
6 min read
Press Releases
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 6, 2026
May 7, 2026
·
2 min read
Press Releases
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 30, 2026
·
4 min read
Press Releases
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
March 5, 2026
·
10 min read
Press Releases
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
March 31, 2026
·
5 min read
Press Releases
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 31, 2026
·
7 min read
Press Releases
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
November 20, 2025
·
2 min read
1 of 48,449
Next
